News & Events
10 May 2012 DIABETES AT THE COALFACE
Following on from the success of last year’s event, I am delighted to announce that the Welsh Conference of the Primary Care Diabetes Society will be held again in Cardiff on 10 May this year.
Hosted by Dr Pam Brown and Dr David Millar-Jones, Welsh representatives of the PCDS, this event will provide you with continuing professional development, an opportunity to learn from some leading diabetes experts in Wales and a chance to network with your peers and discuss the key issues that affect you in day-to-day clinical practice.
Through lectures and interactive masterclasses this event will provide practical guidance to healthcare professionals on issues that impact everyday diabetes practice in Wales. Entitled “Diabetes at the Coalface – Management strategies for type 2 diabetes in Wales”, this year’s event covers topics including:
- Diagnosing diabetes and how to screen for it
- Diabetes therapies: out with the old and in with the new?
- Obesity: a Welsh perspective
New resources due to be launched before this year’s conference will also provide you with extended CPD opportunities, such as online post-event education and tools to help you put in place action plans within your practice.
This cost to attend this event this year has been reduced to £75 for PCDS members* and £95 for non-members. However, by booking before 29 February, you can take advantage of the of the early-bird price of £60 and £75 respectively.
For more information or to book on this exciting conference please click here or call the events team on: 0207 627 1510.
We hope that you will be able to join us at this important and influential event.
Patterns and trends in insulin intensification among patients with type 2 diabetes: A systematic review
Guidelines recommend insulin intensification over time to achieve HbA1c targets ... The paucity of available studies prevented a comprehensive understanding of patterns and trends in insulin intensification. Such information is needed to assess the quality of pharmacologic care for patients with T2DM (Primary Care Diabetes)
Insulin pumps (CSII) and cardiovascular diseases and mortality in the Swedish national diabetes register
This large prospective observational study showed risk reductions of around 5% for cardiovascular diseases and mortality with CSII compared to insulin injections in patients with type 1 diabetes followed for 6 years (Presentation Abstract, EASD)
Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study
24 weeks after switching from basal-bolus insulin regimens to biphasic insulin aspart 30, glycaemic control and HRQoL were significantly improved, and hypoglycaemia was significantly reduced (Primary Care Diabetes)
Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium
This study provides the most definitive quantification to date of an excess risk of pancreatic cancer among diabetics. It also shows that a 30% excess risk persists for more than two decades after diabetes diagnosis, thus supporting a causal role of diabetes in pancreatic cancer. Oral antidiabetics may decrease the risk of pancreatic cancer, whereas insulin showed an inconsistent duration–risk relationship (Annals of Oncology)
Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells
Although S7 cells are not fully equivalent to mature beta cells, their capacity for glucose-responsive insulin secretion and rapid reversal of diabetes in vivo makes them a promising alternative to pancreatic progenitor cells or cadaveric islets for the treatment of diabetes (Nature Biotechnology)